In a significant development, the U.S. House of
Representatives voted in favor of several amendments to protect
cannabis users in legal states. These amendments will prohibit
federal agencies, especially the Department of Justice, from
interfering with cannabis programs, individuals and businesses in
legal states.
The amendments won approval from the U.S. House Rules Committee and
are heading for a voting on the House floor later this week. The
measure would need approval in Senate after getting full House
vote. The committee also instructed the FDA to regulate CBD
products as conventional foods and dietary supplements.
Marijuana Industry is Blooming
The marijuana industry has strong potential especially after its
legalization for recreational and medicinal use. Moreover, the
industry is enjoying benefits of expansion into other industries
like food, beverage, tobacco and cosmetics.
On May 31, the FDA held its first hearing to take a decision on
whether companies can add CBD, a non-intoxicating cannabis
compound, to food, beverages and dietary supplements. Several CBD
manufacturers, researchers, farmers and retailers have urged the
regulatory authority to allow the use of cannabis. In this regard,
the FDAâs approval of CBD-based drug Epidiolex was a major
achievement for the industry.
On Mar 28, the House Financial Services Committee voted 45-15 in
favor of passing the Secure and Fair Enforcement Banking Act of
2019 or the SAFE Banking Act. The bill seeks to safeguard the
process of financial lending to cannabis companies in the United
States.
This bill would not only protect the industryâs credit lines, but
also aid cannabis ancillary industries in the country. The
ancillary sector has been suffering from financial uncertainties
associated with the legal status of marijuana in the past.
Cannabis is getting approval from many U.S. states for recreational
uses, in addition to medical usage. Though pot remains entirely
illegal at the federal level, currently 47 U.S. states offer some
form of legalized marijuana for sale.
Strong Market Potential
According to Arcview Market Researchâs annual report --- "The State
of Legal Cannabis Markets" --- the global cannabis market size is
likely to reach $15 billion this year, implying a gain of 36% year
over year. The report evaluates "total cannabinoid market,"
including sales of medical and recreational cannabis at
dispensaries, hemp-derived products in CBD (non-psychoactive
cannabidiol) and the U.S. FDA approved CBD-based
pharmaceuticals.
As per MGO|ELLO Alliance, investment in U.S cannabis industry
reached $1.3 billion in the first half of 2019. Per Arcview Market
Research and BDS Analytics, cannabis sales in dispensaries, retail
stores and pharmacies are likely to grow nearly $45 billion
globally by 2024. Of this, CBD products are likely to command $20
billion is sales in 2024.
Research firm Cowen projected that the market size of the U.S.
legal cannabis industry will reach $75 billion in by 2030.
According to Barclays, the U.S. cannabis market would be $28
billion if legalized in 2019, and grow to $41 billion by
2028.
Likely Gainers
The marijuana industry is considered extremely volatile. Most of
these companies are in their early stages of development and
characterized as risky for investors. However, cannabis stocks are
solid long-term bets. Of these, stocks with a Zacks Rank #3 (Hold)
or better and having solid long-term growth potential are worth
trying out despite the latent risks. We have narrowed down our
search to five such stocks.
The chart below shows price performance of our five picks year to
date.
Canopy Growth Corp. CGC engages
in growing, possession, and sale of medical cannabis in Canada. Its
products include dried flowers, oils and concentrates, softgel
capsules and hemps. The stock carries a Zacks Rank #2 (Buy). You
can see the complete list of todayâs Zacks #1 Rank (Strong
Buy) stocks here.
The company has an expected earnings growth rate of 45.2% and 72.3%
for the current quarter and current year, respectively. The Zacks
Consensus Estimate for the current quarter and current year has
improved 5.6% and 4.3%, respectively, over the last 60 days. The
stock has surged 49.5% year to date.
GW Pharmaceuticals plc GWPH is a biopharmaceutical
company, focusing on discovering, developing, and commercializing
cannabinoid prescription medicines using botanical extracts derived
from the Cannabis plant. The stock carries a Zacks Rank #2.
The company has an expected earnings growth rate of 89.7% and 90.8%
for the current quarter and next year, respectively. The Zacks
Consensus Estimate for the current quarter and next year has
improved 94.5% and 41.2%, respectively, over the last 60 days. The
stock has surged 78.3% year to date.
The Scotts Miracle-Gro Co. SMG is the worldâs
leading marketer of branded consumer lawn and garden as well as
hydroponic growing products especially pot. In April 2018, the
company acquired hydroponic equipment maker Sunlight Supply to
enter into the pot business. The stock carries a Zacks Rank
#2.
The company has an expected earnings growth rate of 16% and 16.7%
for the current quarter and current year, respectively. The Zacks
Consensus Estimate for the current year has improved 2.4% over the
last 60 days. The stock has surged 59% year to date.
Cronos Group Inc. CRON engages in investment in
firms that are licensed to produce and sell medical marijuana
pursuant to Canada's Marihuana for Medical Purposes Regulations.
The stock carries a Zacks Rank #3. The company has an expected
earnings growth rate of 137.5% for the current year. The Zacks
Consensus Estimate for the current year has improved 200% over the
last 60 days. The stock has surged 53.4% year to date.
Aurora Cannabis Inc. ACB produces and distributes
medical cannabis products. It is vertically integrated and
horizontally diversified across various segments of the cannabis
value chain. The stock carries a Zacks Rank #3. The company has an
expected earnings growth rate of 85% for the next year. The Zacks
Consensus Estimate for the next year has improved 50% over the last
60 days. The stock has surged 47.2% year to date.
More Stock News: This Is Bigger than the
iPhone!
It could become the mother of all technological revolutions. Apple
sold a mere 1 billion iPhones in 10 years but a new breakthrough is
expected to generate more than 27 billion devices in just 3 years,
creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this
fast-emerging phenomenon and 6 tickers for taking advantage of it.
If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>
Want the latest recommendations from Zacks Investment Research?
Today, you can download 7 Best Stocks for the Next 30 Days.
Click to get this free
report
GW Pharmaceuticals PLC
(GWPH) : Free Stock Analysis Report
The Scotts Miracle-Gro
Company (SMG) : Free Stock Analysis Report
Cronos Group Inc. (CRON) :
Free Stock Analysis Report
Aurora Cannabis Inc. (ACB)
: Free Stock Analysis Report
Canopy Growth Corporation
(CGC) : Free Stock Analysis Report
To read this article on
Zacks.com click here.
Zacks Investment Research